Accent Therapeutics DHX9 compound 1

Accent Therapeutics DHX9 compound 1: sourced facts only. name: "Furthermore, compound 1, an orally bioavailable DHX9 inhibitor was used to investigate in vivo efficacy in MSI CRC (LS411N) and MSS CRC (SW480) xenograft models." [DOI:10.1158/1538-7445.am2023-1136]; target: "Furthermore, compound 1, an orally bioavailable DHX9 inhibitor was used to investigate in vivo efficacy in MSI CRC (LS411N) and MSS CRC (SW480) xenograft models." [DOI:10.1158/1538-7445.am2023-1136]; developer: "1Accent Therapeutics, Lexington, MA." [DOI:10.1158/1538-7445.am2023-1136]; modality: "the first identification of potent and selective in vitro and in vivo small molecule inhibitors of DHX9" [DOI:10.1158/1538-7445.am2023-1136]; stage: "Compound 1 was well tolerated across the 28-day treatment period with robust and durable tumor regression (TGI = 105 %) observed in the LS411N tumor xenograft model only." [DOI:10.1158/1538-7445.am2023-1136]